DC-MEETINGPLAY/AVENTRI
6.1.2022 16:02:13 CET | Business Wire | Press release
Today, market leading event software companies MeetingPlay and Aventri announce that they have merged and received a growth equity investment from Sunstone Partners and Camden Partners. Combining the strengths of both companies, they will forge a new path as the dominant, full-service event software provider.
This new event software powerhouse will blend visionary technology and best-in-class service to close all gaps in the planning process, offering the most complete full-service solution for meetings and events of all sizes, from conferences of 200,000+ to meetings with less than 100 attendees. The combined company will become one of the world’s largest event technology companies, servicing customers on a global scale.
In conjunction with the merger, Eric Lochner has been named Chief Executive Officer of the new company. Eric has over 25 years of experience in building technology and technology-enabled services companies, with an impressive record of mergers and acquisitions. “We are excited to bring these two inventive companies together to create a new cutting-edge experience for the meetings and events industry,” said Lochner. “We have a strong opportunity to deepen the process of hosting in-person, hybrid and virtual events and are excited to be able to better support meeting planners and event organizers while offering a wider range of products and experiences.”
Each year, MeetingPlay and Aventri power a combined total of more than 50,000 events, service over 10,000 companies, and elevate the attendee experience for more than 7 million attendees. The unrivaled creativity, service, and ingenuity of each company will be at the forefront of their new company and brand, which will enable their enterprise customers to grow their businesses with best-in-class events of all types and sizes.
Founded in 2011, MeetingPlay is an award-winning technology pioneer, centered around creating innovative solutions for premier in-person, virtual, and hybrid events. The company is known for pushing the envelope on technology advancements and has successfully powered many of the largest, most complex global events to date across numerous industries.
Aventri is the global leader in data-driven, end-to-end event management solutions for virtual, hybrid, and in-person events. The company was founded in 2008. Today, the award-winning platform provides a suite of premium solutions for the entire event lifecycle, from venue sourcing to event marketing, registration, onsite technology, strategic meetings management, data security and privacy, and ROI reporting.
“Two great companies are coming together, leveraging secular tailwinds to increase market share and expand their innovative software capabilities to benefit top companies and brands,” said Sunstone Partners Co-Founder and Managing Director, Michael Biggee. “We’re delighted to continue partnering with them on their exciting future as one company.”
This news comes at a critical time in the meetings and events industry when planners and organizers are seeking to adopt the benefits of virtual and hybrid gatherings while using fewer software integrations. The two companies will integrate their proprietary software platforms to elevate event experiences through a robust lineup of unmatched products to leading companies in the technology, financial services, travel, hospitality, health services, and association markets. This, paired with the highest level of service, will deliver a richer experience for both planners and attendees, while setting the brand apart from competitors. Highlighted capabilities include:
- Event Marketing Website and Registration to create a seamless attendee journey from beginning to end.
- A Virtual and Hybrid Event Platform, which uses novel technology to create lifelike experiences for virtual attendees. The platform provides virtual and onsite attendees with unified engagement features like chat, Q&A, network matchmaking, and video conferencing that enables participants in the same room and across the world to connect instantly.
- A Mobile App and imaginative Onsite Event Solutions, which enrich the attendee experience start to finish, boost engagement, and deliver ROI metrics, while keeping participants safe.
Co-Founder and former MeetingPlay CEO Joe Schwinger, and Co-Founder and former MeetingPlay COO Lisa Vann will remain with the new company and undertake executive roles to continue enhancing the event technology industry and working with their valued customers. Former Aventri CEO Jim Sharpe will remain a shareholder and advisor to the new company.
For more information about MeetingPlay, visit www.meetingplay.com and follow along on Instagram , Twitter , Facebook and LinkedIn .
For more information about Aventri, visit www.aventri.com and follow along on Instagram , Twitter , Facebook and LinkedIn .
About MeetingPlay
MeetingPlay is a Washington D.C.-based technology company focused on creating groundbreaking solutions for in-person, virtual, and hybrid events. With every meeting and event, MeetingPlay creates transformative experiences that enables their customers, attendees, and sponsors to make valuable, face-to-face connections. Market-leading companies entrust MeetingPlay to solve their biggest event challenges. Learn more at meetingplay.com
.
About Aventri
Aventri is the global leader in data-driven, end-to-end event and meeting management solutions for virtual, hybrid, and in-person events. Their award-winning SaaS platform, virtual technology, and best-in-class service offerings have enabled more than 30,000 event professionals annually to plan, promote, deliver, measure, and optimize their events. Aventri’s fully integrated platform’s capabilities include virtual delivery, networking, venue sourcing, registration, marketing, logistics, onsite services, attendee engagement, and data analytics. Headquartered in the United States, the company has offices in the United Kingdom, Europe, and Asia Pacific and has delivered customer events in over 120 countries. Learn more at aventri.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220106005160/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
